Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303073 | 0.87 | TAAR1 (0.52) | APPOPRM1OPRK1KDM4EACKR3 | |
| SCHEMBL10243111 | 0.86 | POLB (0.46) | APPOPRM1OPRK1KDM4EACHE | |
| SCHEMBL10243109 | 0.84 | CHRNB2 (0.48) | GAA | |
| SCHEMBL10243465 | 0.84 | HDAC3 (0.47) | APPOPRM1OPRK1KDM4EBCHE | |
| SCHEMBL10243105 | 0.81 | APP (0.61) | APPBCHEACHE | |
| SCHEMBL13303011 | 0.80 | TAAR1 (0.48) | APPOPRM1OPRK1KDM4EACKR3 | |
| SCHEMBL10243384 | 0.80 | ALDH1A1 (0.49) | KDM4EGAA | |
| SCHEMBL10243171 | 0.79 | KDM4E (0.49) | APPOPRM1OPRK1KDM4EGAA | |
| SCHEMBL13037027 | 0.79 | EPHX1 (0.50) | KDM4EACHE | |
| SCHEMBL10243147 | 0.79 | CDYL (0.49) | APPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | APP 4678/4885OPRM1 4835/4885OPRK1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.